TCTR20211027002已完成2 期
Immunogenicity after booster dose with mRNA BNT162b2 among elderly or adult with underlying diseases who had received AZD1222 using standard versus low dose via intramuscular route (COVID-19)
ational Vaccine Institute0 个研究点目标入组 100 人开始时间: 2021年10月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
The fractional low-dose BNT162b2 mRNA booster vaccine provided non-inferior immunogenicity responses. During a shortage of vaccine supply, a fractional low dose should be considered for a booster vaccination program.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 69 Years（—）
- 性别
- All
入选标准
- •1.Participants must age 18 to 69 years old on the day of vaccination and meet either cohort inclusion criteria.
- •oCohort 1: Participants must age 60 to 69 years old on the day of vaccination.
- •oCohort 2: Participants must have underlying disease e.g., diabetes mellitus, chronic kidney disease, cardiovascular disease.
- •oCohort 3: Participants must be considered immunocompromised e.g., currently taking immunosuppressant, active cancer currently on treatment.
- •oCohort 4 (Control): Participants must age 18 to 59 years old and be in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator.
- •2.Participants must have received 2 doses of AZD1222 vaccination with interval at least 8 weeks apart.
- •3.Participants must have received 2nd dose of AZD1222 for more than 60 days at the day of vaccination.
- •4.Participants must be able to communicate effectively with study personnel and considered reliable, willing, and cooperative in terms of compliance with the protocol requirements.
- •5.Participants must sign a written informed consent form, including any required privacy authorization form, prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
排除标准
- •1.Known anaphylaxis to any of the trial vaccine components (including excipients of the trial vaccines) or drugs.
- •2.Participants with previous documented SARS-CoV-2 infection within 6 months of vaccination day by history obtained from participant(s) and/or positive anti-nucleocapsid test(s).
- •3.Receipt of immunoglobulins or blood products within 3 months on the day of vaccination.
- •4.Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial.
研究者
相似试验
尚未招募
不适用
Immunogenicity of 2 dose regimen of BNT162b2 mRNA vaccine in Thai children aged 6 months to 4 years following COVID 19 (COVID-19)Prevention of COVID-19 with 2-dose mRNA vaccine among healthy Children 6 month to 4 years who had COVID-19 infectionSARS-CoV-2, mRNA vaccine, Infant, Children, Immunogenicity, ReactogenicityTCTR20221018008Ratchadaphisek Sompoch Research Fund80
已完成
1 期
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 boosterThe immunogenicity and safety of BNT162b2 as a booster dose following fully immunized with inactivated vaccine in Thai children aged 5-11 years.SARS-CoV-2, Inactivated SARS-CoV-2 vaccine, BNT162b2, Children, BoosterTCTR20220330001ational Vaccine Institute60
已完成
不适用
ong term immunogenicity of BNT162b2 vaccination and attitudes toward COVID-19 booster vaccines in Thai childreimmunogenecity of SARS-CoV-2 mRNA vaccine, vaccine hesitancySARS-CoV-2, mRNA vaccine, booster vaccination, Immunogenicity, immune waning, vaccine hesitancyTCTR20220301002Ratchadapisek Research Funds240
已完成
4 期
Intradermal COVID-19 vaccine for immune-mediated dermatologic disease patientpsoriasisautoimmune bullous diseases COVID-19 vaccine's immunogenicity COVID-19 vaccine's reactogenicitypsoriasisbullous dermatosisCOVID-19 VaccinesBNT162 VaccineTCTR20220524004Faculty of Medicine Ramathibodi Hospital109
已完成
不适用
Covid-19 Vaccine Response in Elderly SubjectsCovid19 VaccineNCT04760704University Hospital, Lille264